A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Preserved Ejection Fraction (HFpEF) (EMPERIAL - Preserved)
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009489/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus
placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic
heart failure (CHF) with preserved ejection fraction (LVEF > 40%).
Secondary objectives are to assess Patient-Reported Outcome (PRO)
提供机构：
Vivli
创建时间：
2023-12-13
